Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fenofibrate is a lipid-lowering agent of the fibrate class that acts primarily as an agonist of peroxisome proliferator-activated receptor alpha (PPARα), leading to increased lipolysis and reduced triglyceride levels. It is used to treat primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia. Coenzyme Q10 (ubiquinone) is a vitamin-like compound essential for mitochondrial electron transport and cellular energy production; it also has antioxidant properties. The combination of fenofibrate with coenzyme Q10 has been studied for its potential to improve endothelial function in type 2 diabetes by addressing both dyslipidemia and oxidative stress. Preclinical studies suggest that coenzyme Q10 may mitigate skeletal muscle toxicity associated with fenofibrate by reducing oxidative stress and apoptosis[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fenofibrate + coenzyme Q10.